Dupont pharmaceuticals study 006 for Sustiva.

Research output: Contribution to journalArticle

Abstract

Dupont Pharmaceutical studies have demonstrated the efficacy of efavirenz with AZT and 3TC in treatment-naive patients. When compared to a protease inhibitor regimen, 95 percent of the patients taking the efavirenz combination achieved a viral load of less than 400 copies/ml at 24 weeks. Abacavir is also attracting attention due to its potency and dosing convenience. Abacavir has contributed to lower viral loads in treatment naive patients when combined with ZDV and 3TC. Both efavirenz and abacavir should be available in the Fall.

Original languageEnglish (US)
Pages (from-to)1
Number of pages1
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume10
Issue number5
StatePublished - 1998
Externally publishedYes

Fingerprint

efavirenz
Lamivudine
Viral Load
Pharmaceutical Preparations
Protease Inhibitors
Therapeutics
abacavir

Cite this

@article{3e1dc88abb6a4d3aba6451f0a23a3ed0,
title = "Dupont pharmaceuticals study 006 for Sustiva.",
abstract = "Dupont Pharmaceutical studies have demonstrated the efficacy of efavirenz with AZT and 3TC in treatment-naive patients. When compared to a protease inhibitor regimen, 95 percent of the patients taking the efavirenz combination achieved a viral load of less than 400 copies/ml at 24 weeks. Abacavir is also attracting attention due to its potency and dosing convenience. Abacavir has contributed to lower viral loads in treatment naive patients when combined with ZDV and 3TC. Both efavirenz and abacavir should be available in the Fall.",
author = "John Bartlett",
year = "1998",
language = "English (US)",
volume = "10",
pages = "1",
journal = "The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service",
issn = "1551-8396",
publisher = "Johns Hopkins University Press",
number = "5",

}

TY - JOUR

T1 - Dupont pharmaceuticals study 006 for Sustiva.

AU - Bartlett, John

PY - 1998

Y1 - 1998

N2 - Dupont Pharmaceutical studies have demonstrated the efficacy of efavirenz with AZT and 3TC in treatment-naive patients. When compared to a protease inhibitor regimen, 95 percent of the patients taking the efavirenz combination achieved a viral load of less than 400 copies/ml at 24 weeks. Abacavir is also attracting attention due to its potency and dosing convenience. Abacavir has contributed to lower viral loads in treatment naive patients when combined with ZDV and 3TC. Both efavirenz and abacavir should be available in the Fall.

AB - Dupont Pharmaceutical studies have demonstrated the efficacy of efavirenz with AZT and 3TC in treatment-naive patients. When compared to a protease inhibitor regimen, 95 percent of the patients taking the efavirenz combination achieved a viral load of less than 400 copies/ml at 24 weeks. Abacavir is also attracting attention due to its potency and dosing convenience. Abacavir has contributed to lower viral loads in treatment naive patients when combined with ZDV and 3TC. Both efavirenz and abacavir should be available in the Fall.

UR - http://www.scopus.com/inward/record.url?scp=0032149801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032149801&partnerID=8YFLogxK

M3 - Article

C2 - 11365772

AN - SCOPUS:0032149801

VL - 10

SP - 1

JO - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

JF - The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service

SN - 1551-8396

IS - 5

ER -